Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

DexCom Inc Stock Research

DXCM

87.50USD-1.58(-1.77%)Delayed
Watchlist

Market Summary

USD87.50-1.58
Delayed
-1.77%

DXCM Alerts

  • 2 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

DXCM Stock Price

DXCM RSI Chart

DXCM Valuation

Market Cap

33.8B

Price/Earnings (Trailing)

94.5

Price/Sales (Trailing)

10.57

EV/EBITDA

47.66

Price/Free Cashflow

72.5

DXCM Price/Sales (Trailing)

DXCM Profitability

EBT Margin

13.87%

Return on Equity

13.1%

Return on Assets

5.3%

Free Cashflow Yield

1.38%

DXCM Fundamentals

DXCM Revenue

Revenue (TTM)

3.2B

Revenue Y/Y

25.15%

Revenue Q/Q

17.51%

DXCM Earnings

Earnings (TTM)

357.5M

Earnings Y/Y

127.7%

Earnings Q/Q

138.48%

Price Action

52 Week Range

78.94139.55
(Low)(High)

Last 7 days

-9.2%

Last 30 days

-16.2%

Last 90 days

-31.0%

Trailing 12 Months

8.1%

DXCM Financial Health

Current Ratio

2.02

DXCM Investor Care

Buy Backs (1Y)

1.63%

Diluted EPS (TTM)

0.86

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for DXCM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-15
ALTMAN STEVEN R
sold
-101,495
101
-1,000
-
2023-09-12
Heller Bridgette P
sold
-63,936
106
-600
-
2023-09-11
Selvaraj Shelly Ramasamy
back to issuer
-215,241
105
-2,045
svp chief information officer
2023-09-01
Dolan Matthew Vincent
sold
-5,729
102
-56.00
svp corporate strategy-develop
2023-08-24
Driscoll Rimma
acquired
-
-
4,008
-
2023-08-23
Pacelli Steven Robert
sold
-43,989
107
-411
evp managing director dexcom v
2023-08-22
Sylvain Jereme M
sold
-192,477
104
-1,844
evp chief financial officer
2023-08-11
Dahut Karen M
gifted
-
-
-1,544
-
2023-08-11
Dahut Karen M
gifted
-
-
1,544
-
2023-08-09
Stern Sadie
sold
-43,398
110
-392
evp chief human resources offi

1–10 of 50

Which funds bought or sold DXCM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
new
-
766,419
766,419
0.01%
2023-09-20
BARCLAYS PLC
added
89.26
53,350,000
102,139,000
0.06%
2023-09-12
Farther Finance Advisors, LLC
added
1.18
4,706
44,207
0.01%
2023-09-12
Prosperity Financial Group, Inc.
added
6.62
45,637
300,071
0.26%
2023-09-11
BLUEFIN CAPITAL MANAGEMENT, LLC
new
-
31,818,100
31,818,100
6.08%
2023-09-07
ST GERMAIN D J CO INC
new
-
1,028
1,028
-%
2023-09-07
JAG CAPITAL MANAGEMENT, LLC
reduced
-1.04
878,516
10,161,400
1.17%
2023-09-05
Covenant Partners, LLC
added
2.58
65,443
551,308
0.20%
2023-08-29
EFG Asset Management (Americas) Corp.
reduced
-10.21
-3,062
447,600
0.10%
2023-08-28
DT Investment Partners, LLC
unchanged
-
227
7,808
-%

1–10 of 40

Latest Funds Activity

Are funds buying DXCM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DXCM
No. of Funds

Schedule 13G FIlings of DexCom

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 10, 2023
blackrock inc.
8.7%
33,535,680
SC 13G/A
Feb 09, 2023
vanguard group inc
11.34%
43,819,836
SC 13G/A
Jan 27, 2023
blackrock inc.
8.7%
33,882,680
SC 13G/A
Jan 25, 2023
blackrock inc.
8.8%
33,882,680
SC 13G/A
Feb 09, 2022
vanguard group inc
10.74%
10,410,319
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 08, 2022
blackrock inc.
8.4%
8,128,454
SC 13G/A
Dec 06, 2021
baillie gifford & co
4.85%
4,700,380
SC 13G/A
Feb 16, 2021
price t rowe associates inc /md/
2.2%
2,139,304
SC 13G/A
Feb 10, 2021
vanguard group inc
10.66%
10,232,245
SC 13G/A

Recent SEC filings of DexCom

View All Filings
Date Filed Form Type Document
Sep 22, 2023
144
Notice of Insider Sale Intent
Sep 22, 2023
4
Insider Trading
Sep 19, 2023
4
Insider Trading
Sep 15, 2023
144
Notice of Insider Sale Intent
Sep 13, 2023
4
Insider Trading
Sep 12, 2023
144
Notice of Insider Sale Intent
Sep 12, 2023
4
Insider Trading
Sep 01, 2023
4
Insider Trading
Aug 28, 2023
3
Insider Trading
Aug 28, 2023
8-K
Current Report

DXCM Fair Value

Loading...

Peers (Alternatives to DexCom)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
108.3B
19.5B
3.38% 36.58%
39.99
5.57
10.36% 30.30%
101.2B
6.7B
-0.75% 50.83%
71.05
15.19
11.75% -0.66%
77.5B
13.4B
6.45% 36.39%
85
5.78
8.69% 3.17%
71.3B
19.0B
-4.29% 12.66%
44.09
3.79
0.46% -5.24%
42.3B
5.7B
-8.22% -17.24%
30.48
7.49
5.64% -4.53%
MID-CAP
9.5B
937.8M
-2.12% 37.22%
325.65
10.11
16.30% 250.21%
7.1B
616.6M
-12.54% -24.86%
29.24
11.56
69.52% 343.68%
5.1B
1.1B
-6.10% -12.07%
24.23
4.65
12.63% 50.85%
2.6B
452.1M
-21.20% -33.94%
-26.32
5.78
24.99% 24.09%
1.3B
790.3M
-27.09% -56.49%
-5.97
1.69
3.21% -1604.53%
SMALL-CAP
1.6B
421.8M
-15.15% 56.11%
-9.32
3.69
44.49% -2.43%
947.4M
780.7M
-7.75% -9.65%
-26.32
1.21
4.68% -510.17%
839.3M
239.8M
0.70% 0.15%
-22.16
3.5
-4.74% -31.15%
609.7M
162.9M
-27.67% -61.65%
-11.53
3.74
42.67% 12.82%

DexCom News

MarketBeat
Integrated Advisors Network LLC Purchases 4010 Shares of ....
MarketBeat,
4 hours ago
The Motley Fool
Best Stocks

Returns for DXCM

Cumulative Returns on DXCM

28.7%


10-Year Cumulative Returns

20.7%


7-Year Cumulative Returns

20.2%


5-Year Cumulative Returns

-4.2%


3-Year Cumulative Returns

Risks for DXCM

What is the probability of a big loss on DXCM?

90%


Probability that DexCom stock will be more than 20% underwater in next one year

26.1%


Probability that DexCom stock will be more than 30% underwater in next one year.

23.1%


Probability that DexCom stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does DXCM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if DexCom was unfortunately bought at previous high price.

Drawdowns

Financials for DexCom

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue5.8%3,1983,0232,9102,7932,6732,5722,4492,3192,1702,0271,9271,8211,7161,6011,4761,3511,2221,1281,032915833
Gross Profit5.0%2,0451,9481,8831,8141,7671,7351,6811,6071,5011,3681,2801,1901,0971,019932845767714664595553
Operating Expenses3.0%1,5961,5511,4921,5481,5301,4741,4151,2381,1561,056981893838829789969933884850604577
  S&GA Expenses4.5%1,1241,0761,000936900838807747707657618574539541516499479452433414393
  R&D Expenses-0.5%465467484518536544517487445396360320299288274252236214200191184
EBITDA-100.0%-599565434385366376440416393377374330266213------
EBITDA Margin-100.0%-0.20*0.19*0.16*0.14*0.14*0.15*0.19*0.19*0.19*0.20*0.21*0.19*0.17*0.14*------
Interest Expenses6.5%20.0019.0019.0019.0019.0019.0019.00-28.30-8.507.0018.0075.0066.0061.0060.0053.0043.0033.0023.0019.0019.00
Earnings Before Taxes20.0%503419391264230252257405368317298238209153104-167-168-129-12659.0012.00
EBT Margin-100.0%-0.14*0.13*0.09*0.05*0.07*0.07*0.13*0.13*0.11*0.12*0.13*0.12*0.10*0.07*------
Net Income22.2%358293341244230258217634618586550231205148101-171-170-129-12743.00-5.40
Net Income Margin-100.0%-0.10*0.12*0.09*0.06*0.09*0.06*0.24*0.26*0.25*0.26*0.13*0.12*0.09*0.07*------
Free Cashflow-100.0%-41630526121695.0053.00140101236277264209131135------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets23.7%6,8215,5165,3924,8995,2175,0574,9334,7764,5044,3904,2913,8333,5222,4482,3952,1862,0661,9741,9161,1141,008
  Current Assets32.8%5,0033,7673,6693,3993,8093,7473,6843,6563,4743,4453,4253,2373,0331,9961,9691,8161,7441,6911,700914836
    Cash Equivalents91.7%1,1956236426987357161,0541,4441,1597348186745305854463967091,2851,137367300
  Inventory15.1%42136630731134034235735131929023520116514212012011810171.0055.0046.00
  Net PPE-100.0%-1,0761,0561,003943857802742676590515462384346321301253221183170157
  Goodwill0.4%26.0026.0026.0025.0026.0027.0027.0024.0019.0019.0019.0019.0019.0019.0019.0018.0019.0019.0019.0018.0012.00
Liabilities43.8%4,7203,2833,2603,0752,9622,8682,8912,6402,5062,4872,4642,3342,1681,5131,5121,4211,3781,3051,253552525
  Current Liabilities11.0%2,0701,8651,839901807711721735601604614506400343360322288235222194171
Shareholder's Equity-5.9%2,1002,2332,1321,8252,2562,1892,0421,9121,7551,6451,5521,4991,354935883764688669663562482
  Retained Earnings21.9%644529480388287236139-28.00-98.90-161-78.20-557-629-675-695-788-834-823-798-619-665
  Additional Paid-In Capital-1.6%2,2692,3062,2582,0722,0291,9972,1092,3222,1942,1621,7272,1542,0801,7071,6761,6521,6201,5911,5611,1821,149
Accumulated Depreciation--------------------72.0066.00
Shares Outstanding-0.4%386388386386393389388387387385384383375367366365364361360354353
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations2.3%771754670643597486443509409502476447394305315205167144123131110
  Share Based Compensation5.4%140133127119116115113121124124119109103102103104106102102102101
Cashflow From Investing-138.7%-707-296-521-823-1,023-515-216256218-1,260-1,018-1,088-1,491-1,015-1,015-890-4727.00-139-171-213
Cashflow From Financing172.7%397-546-552-55211.0015.0010.006.00-90691291791812.0011.007127127117109.008.00
  Buy Backs-1,115-5581,115--------------100--

DXCM Income Statement

2023-06-30
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue$ 871.3$ 696.2$ 1,612.8$ 1,325.0
Cost of sales324.9246.7603.8477.4
Gross profit546.4449.51,009.0847.6
Operating expenses:    
Research and development119.3121.7238.3257.6
Amortization of intangible assets1.71.93.53.9
Selling, general and administrative297.3248.9591.9467.8
Total operating expenses418.3372.5833.7729.3
Operating income128.177.0175.3118.3
Interest expense(5.9)(4.7)(10.5)(9.3)
Income from equity investments0.00.00.00.2
Interest and other income, net37.13.059.02.2
Income before income taxes159.375.3223.8111.4
Income tax expense (benefit)43.424.459.3(36.8)
Net income$ 115.9$ 50.9$ 164.5$ 148.2
Basic net income per share (USD per share)$ 0.30$ 0.13$ 0.43$ 0.38
Shares used to compute basic net income per share (shares)386.7392.5386.7390.7
Diluted net income per share (USD per share)$ 0.28$ 0.12$ 0.40$ 0.36
Shares used to compute diluted net income per share (shares)431.5421.4426.6429.1

DXCM Balance Sheet

2023-06-30
Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,194.9$ 642.3
Short-term marketable securities2,441.31,813.9
Accounts receivable, net750.6713.3
Inventory421.1306.7
Prepaid and other current assets195.0192.6
Total current assets5,002.93,668.8
Property and equipment, net1,077.61,055.6
Operating lease right-of-use assets76.380.0
Goodwill25.825.7
Intangibles, net154.2173.3
Deferred tax assets417.0341.2
Other assets66.947.1
Total assets6,820.75,391.7
Current liabilities:  
Accounts payable and accrued liabilities1,156.5901.8
Accrued payroll and related expenses108.6134.3
Current portion of long-term senior convertible notes773.8772.6
Short-term operating lease liabilities21.820.5
Deferred revenue9.010.1
Total current liabilities2,069.71,839.3
Long-term senior convertible notes2,430.61,197.7
Long-term operating lease liabilities86.994.6
Other long-term liabilities133.1128.3
Total liabilities4,720.33,259.9
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 20220.00.0
Common stock, $0.001 par value, 800.0 million shares authorized; 394.6 million and 386.1 million shares issued and outstanding, respectively, at June 30, 2023; and 393.2 million and 386.3 million shares issued and outstanding, respectively, at December 31, 20220.40.4
Additional paid-in capital2,269.02,258.1
Accumulated other comprehensive loss(29.3)(11.6)
Retained earnings644.4479.9
Treasury stock, at cost; 8.5 million shares at June 30, 2023 and 6.9 million shares at December 31, 2022(784.1)(595.0)
Total stockholders’ equity2,100.42,131.8
Total liabilities and stockholders’ equity$ 6,820.7$ 5,391.7
Kevin R. Sayer
6300
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.